Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Genetics Completes Final Tranche of $28.4M Series B Financing

NEW YORK (GenomeWeb) – Atlas Genetics today announced it completed the final tranche of its £16.9 million ($28.4 million) Series B financing to complete the transfer to manufacture of its io molecular diagnostics system and file for regulatory approval of the first test for chlamydia.

Investors in the financing included Novartis Venture Funds, Consort Medical, Life Sciences Partners, BB Biotech Ventures, Johnson & Johnson Development, YFM Equity Partners, and private investors.

The io system uses electrochemical sensor technology to diagnose infectious diseases, such as sexually transmitted diseases and hospital-acquired infections. Atlas said that in addition to use in hospital settings, the platform is aimed at primary care clinics and doctor's offices, where it will enable practitioners to test for infectious diseases as accurately as hospital laboratories.

"This will enable clinicians to test and commence treatment within the same appointment and ensure much improved compliance, particularly in the area of [STDs], where a significant proportion of patients fail to return for test results or follow-on treatment," the Bath, UK-based company said in a statement.

The firm completed development of the instrument earlier this year and entered into the pilot manufacturing phase.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.